{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:07:39Z","timestamp":1791119259792,"version":"4.1.0"},"reference-count":157,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1097\/wnf.0b013e3181880359","type":"journal-article","created":{"date-parts":[[2009,5,28]],"date-time":"2009-05-28T03:17:58Z","timestamp":1243480678000},"page":"121-132","source":"Crossref","is-referenced-by-count":75,"title":["Update on Inflammation, Neurodegeneration, and Immunoregulation in Multiple Sclerosis"],"prefix":"10.1097","volume":"32","author":[{"given":"Jeffrey L.","family":"Bennett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"St\u00fcve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210203","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuron.2006.09.011","article-title":"The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration.","volume":"52","author":"Hauser","year":"2006","journal-title":"Neuron"},{"key":"R2-1-20210203","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ana.20016","article-title":"Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion.","volume":"55","author":"Barnett","year":"2004","journal-title":"Ann Neurol"},{"key":"R3-1-20210203","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/archneur.64.1.76","article-title":"Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis.","volume":"64","author":"Bo","year":"2007","journal-title":"Arch Neurol"},{"key":"R4-1-20210203","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ana.1123","article-title":"Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.","volume":"50","author":"Peterson","year":"2001","journal-title":"Ann Neurol"},{"key":"R5-1-20210203","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/brain\/awl074","article-title":"The contribution of demyelination to axonal loss in multiple sclerosis.","volume":"129","author":"DeLuca","year":"2006","journal-title":"Brain"},{"key":"R6-1-20210203","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jneuroim.2006.11.015","article-title":"Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis.","volume":"184","author":"Peterson","year":"2007","journal-title":"J Neuroimmunol"},{"key":"R7-1-20210203","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-510X(02)00191-0","article-title":"Remyelination in multiple sclerosis.","volume":"206","author":"Bruck","year":"2003","journal-title":"J Neurol Sci"},{"key":"R8-1-20210203","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJM200011163432010","article-title":"Relapse, remission, and progression in multiple sclerosis.","volume":"343","author":"McDonald","year":"2000","journal-title":"N Engl J Med"},{"key":"R10-1-20210203","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s11882-007-0042-y","article-title":"The spectrum of multiple sclerosis.","volume":"7","author":"Heard","year":"2007","journal-title":"Curr Allergy Asthma Rep"},{"key":"R11-1-20210203","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMra052130","article-title":"Multiple sclerosis-the plaque and its pathogenesis.","volume":"354","author":"Frohman","year":"2006","journal-title":"N Engl J Med"},{"key":"R12-1-20210203","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ana.410050104","article-title":"Multiple sclerosis in the Faroe Islands: I. clinical and epidemiological features.","volume":"5","author":"Kurtzke","year":"1979","journal-title":"Ann Neurol"},{"key":"R13-1-20210203","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/brain\/awh624","article-title":"Role of return migration in the emergence of multiple sclerosis in the French West Indies.","volume":"128","author":"Cabre","year":"2005","journal-title":"Brain"},{"key":"R14-1-20210203","doi-asserted-by":"crossref","first-page":"12877","DOI":"10.1073\/pnas.1932604100","article-title":"Twin concordance and sibling recurrence rates in multiple sclerosis.","volume":"100","author":"Willer","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-1-20210203","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1474-4422(03)00663-X","article-title":"Genetics of multiple sclerosis.","volume":"3","author":"Dyment","year":"2004","journal-title":"Lancet Neurol"},{"key":"R16-1-20210203","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0022-510X(82)90241-6","article-title":"Oligoclonal IgG in the cerebrospinal fluid of guinea pigs with acute experimental allergic encephalomyelitis.","volume":"53","author":"Rostami","year":"1982","journal-title":"J Neurol Sci"},{"key":"R17-1-20210203","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/BF00965892","article-title":"Oligoclonal IgG in rabbits with experimental allergic encephalomyelitis: non-reactivity of the bands with sensitizing neural antigens.","volume":"7","author":"Whitacre","year":"1982","journal-title":"Neurochem Res"},{"key":"R18-1-20210203","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0022-510X(82)90042-9","article-title":"Humoral immunity in chronic relapsing experimental autoimmune encephalomyelitis. The major oligoclonal IgG bands are antibodies to mycobacteria.","volume":"57","author":"Glynn","year":"1982","journal-title":"J Neurol Sci"},{"key":"R19-1-20210203","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1146\/annurev.iy.08.040190.003051","article-title":"The T lymphocyte in experimental allergic encephalomyelitis.","volume":"8","author":"Zamvil","year":"1990","journal-title":"Annu Rev Immunol"},{"key":"R20-1-20210203","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.","volume":"13","author":"O'Connor","year":"2007","journal-title":"Nat Med"},{"key":"R21-1-20210203","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1056\/NEJM197710202971602","article-title":"In vitro cell-mediated immunity of cerebrospinal-fluid lymphocytes to myelin basic protein in primary demyelinating diseases.","volume":"297","author":"Lisak","year":"1977","journal-title":"N Engl J Med"},{"key":"R22-1-20210203","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/ana.20743","article-title":"Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis.","volume":"58","author":"Sriram","year":"2005","journal-title":"Ann Neurol"},{"key":"R23-1-20210203","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ana.20913","article-title":"How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis.","volume":"60","author":"Steinman","year":"2006","journal-title":"Ann Neurol"},{"key":"R24-1-20210203","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann Neurol"},{"key":"R25-1-20210203","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ana.21311","article-title":"Homogeneity of active demyelinating lesions in established multiple sclerosis.","volume":"63","author":"Breij","year":"2008","journal-title":"Ann Neurol"},{"key":"R26-1-20210203","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(05)67102-4","article-title":"Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.","volume":"366","author":"Keegan","year":"2005","journal-title":"Lancet"},{"key":"R27-1-20210203","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(07)70243-0","article-title":"Primary-progressive multiple sclerosis.","volume":"6","author":"Miller","year":"2007","journal-title":"Lancet Neurol"},{"key":"R28-1-20210203","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","article-title":"Multiple sclerosis: an immune or neurodegenerative disorder?","volume":"31","author":"Trapp","year":"2008","journal-title":"Annu Rev Neurosci"},{"key":"R29-1-20210203","doi-asserted-by":"crossref","first-page":"e664","DOI":"10.1371\/journal.pone.0000664","article-title":"HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis.","volume":"2","author":"Brynedal","year":"2007","journal-title":"PLoS ONE"},{"key":"R30-1-20210203","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1468-1331.2007.01825.x","article-title":"The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients.","volume":"14","author":"Smestad","year":"2007","journal-title":"Eur J Neurol"},{"key":"R31-1-20210203","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1056\/NEJMe078147","article-title":"Old suspects found guilty-the first genome profile of multiple sclerosis.","volume":"357","author":"Peltonen","year":"2007","journal-title":"N Engl J Med"},{"key":"R32-1-20210203","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa073493","article-title":"Risk alleles for multiple sclerosis identified by a genomewide study.","volume":"357","author":"Hafler","year":"2007","journal-title":"N Engl J Med"},{"key":"R33-1-20210203","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/ng2103","article-title":"Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.","volume":"39","author":"Gregory","year":"2007","journal-title":"Nat Genet"},{"key":"R34-1-20210203","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm1492","article-title":"Interleukin-10 determines viral clearance or persistence in vivo.","volume":"12","author":"Brooks","year":"2006","journal-title":"Nat Med"},{"key":"R35-1-20210203","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/187153007780059414","article-title":"Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006.","volume":"7","author":"Kleinschnitz","year":"2007","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"R36-1-20210203","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1567202043480152","article-title":"Multiple sclerosis-a coordinated immune attack across the blood brain barrier.","volume":"1","author":"Hemmer","year":"2004","journal-title":"Curr Neurovasc Res"},{"key":"R37-1-20210203","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMra052723","article-title":"The many roles of chemokines and chemokine receptors in inflammation.","volume":"354","author":"Charo","year":"2006","journal-title":"N Engl J Med"},{"key":"R38-1-20210203","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1179\/016164106X98107","article-title":"The role of CD4+ T-cells in the development of MS.","volume":"28","author":"Delgado","year":"2006","journal-title":"Neurol Res"},{"key":"R39-1-20210203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0074-7742(07)79003-7","article-title":"The role of CD4 T cells in the pathogenesis of multiple sclerosis.","volume":"79","author":"Chitnis","year":"2007","journal-title":"Int Rev Neurobiol"},{"key":"R40-1-20210203","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/archneur.57.8.1183","article-title":"Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis.","volume":"57","author":"Khoury","year":"2000","journal-title":"Arch Neurol"},{"key":"R41-1-20210203","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/brain\/awl179","article-title":"Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients.","volume":"129","author":"Rinaldi","year":"2006","journal-title":"Brain"},{"key":"R42-1-20210203","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2006.05.006","article-title":"Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters.","volume":"177","author":"Laplaud","year":"2006","journal-title":"J Neuroimmunol"},{"key":"R43-1-20210203","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T cell clone: I. definition according to profiles of lymphokine activities and secreted proteins.","volume":"136","author":"Mosmann","year":"1986","journal-title":"J Immunol"},{"key":"R44-1-20210203","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0167-5699(97)01102-X","article-title":"TH1-TH2: reliable paradigm or dangerous dogma?","volume":"18","author":"Allen","year":"1997","journal-title":"Immunol Today"},{"key":"R45-1-20210203","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni0603-503","article-title":"TH1-TH2: a procrustean paradigm.","volume":"4","author":"Gor","year":"2003","journal-title":"Nat Immunol"},{"key":"R46-1-20210203","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4049\/jimmunol.150.2.353","article-title":"Human IL-10 is produced by both type 1 helper (TH1) and type 2 helper (TH2) T cell clones and inhibits their antigen-specific proliferation and cytokine production.","volume":"150","author":"Del Prete","year":"1993","journal-title":"J Immunol"},{"key":"R47-1-20210203","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"R48-1-20210203","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4049\/jimmunol.178.3.1341","article-title":"T-bet regulates the fate of TH1 and TH17 lymphocytes in autoimmunity.","volume":"178","author":"Gocke","year":"2007","journal-title":"J Immunol"},{"key":"R49-1-20210203","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1084\/jem.192.3.393","article-title":"Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction.","volume":"192","author":"Babbe","year":"2000","journal-title":"J Exp Med"},{"key":"R50-1-20210203","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1182\/blood-2003-11-4025","article-title":"High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay.","volume":"103","author":"Crawford","year":"2004","journal-title":"Blood"},{"key":"R51-1-20210203","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/brain\/awf059","article-title":"Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients.","volume":"125","author":"Jacobsen","year":"2002","journal-title":"Brain"},{"key":"R52-1-20210203","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jneuroim.2006.06.010","article-title":"Phenotypic characterization of autoreactive T cells in multiple sclerosis.","volume":"178","author":"Ratts","year":"2006","journal-title":"J Neuroimmunol"},{"key":"R53-1-20210203","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.7624779","article-title":"Induction of MHC class I genes in neurons.","volume":"269","author":"Neumann","year":"1995","journal-title":"Science"},{"key":"R54-1-20210203","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4049\/jimmunol.171.1.368","article-title":"Vulnerability of human neurons to T cell-mediated cytotoxicity.","volume":"171","author":"Giuliani","year":"2003","journal-title":"J Immunol"},{"key":"R55-1-20210203","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1073\/pnas.0308689100","article-title":"Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood.","volume":"101","author":"Skulina","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R56-1-20210203","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0002-9440(10)61755-5","article-title":"Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes.","volume":"159","author":"Medana","year":"2001","journal-title":"Am J Pathol"},{"key":"R57-1-20210203","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1126\/science.3317824","article-title":"The T cell receptor.","volume":"238","author":"Marrack","year":"1987","journal-title":"Science"},{"key":"R58-1-20210203","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.4049\/jimmunol.174.8.4678","article-title":"Gamma delta T cells regulate the extent and duration of inflammation in the central nervous system by a Fas ligand-dependent mechanism.","volume":"174","author":"Ponomarev","year":"2005","journal-title":"J Immunol"},{"key":"R59-1-20210203","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1073\/pnas.90.3.923","article-title":"Clonal expansions of activated gamma\/delta T cells in recent-onset multiple sclerosis.","volume":"90","author":"Shimonkevitz","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R60-1-20210203","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.4049\/jimmunol.164.4.2120","article-title":"Experimental autoimmune encephalomyelitis on the SJL mouse: effect of gamma delta T cell depletion on chemokine and chemokine receptor expression in the central nervous system.","volume":"164","author":"Rajan","year":"2000","journal-title":"J Immunol"},{"key":"R61-1-20210203","doi-asserted-by":"crossref","first-page":"941","DOI":"10.4049\/jimmunol.157.2.941","article-title":"A pathogenic role for gamma delta T cells in relapsing-remitting experimental allergic encephalomyelitis in the SJL mouse.","volume":"157","author":"Rajan","year":"1996","journal-title":"J Immunol"},{"key":"R62-1-20210203","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.4049\/jimmunol.160.12.5955","article-title":"The effect of gammadelta T cell depletion on cytokine gene expression in experimental allergic encephalomyelitis.","volume":"160","author":"Rajan","year":"1998","journal-title":"J Immunol"},{"key":"R63-1-20210203","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.4049\/jimmunol.173.3.1587","article-title":"Gamma delta T cell regulation of IFN-gamma production by central nervous system-infiltrating encephalitogenic T cells: correlation with recovery from experimental autoimmune encephalomyelitis.","volume":"173","author":"Ponomarev","year":"2004","journal-title":"J Immunol"},{"key":"R64-1-20210203","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1179\/016164106X98099","article-title":"The B cell response in multiple sclerosis.","volume":"28","author":"Owens","year":"2006","journal-title":"Neurol Res"},{"key":"R65-1-20210203","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00000441-195001000-00009","article-title":"A study of the crystalline albumin, gamma globulin and total protein in the cerebrospinal fluid of 100 cases of multiple sclerosis and in other diseases.","volume":"219","author":"Kabat","year":"1950","journal-title":"Am J Med Sci"},{"key":"R66-1-20210203","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00329158","article-title":"Biochemical findings in multiple sclerosis: III. Immunoglobulins of restricted heterogeneity and light chain distribution in cerebrospinal fluid of patients with multiple sclerosis.","volume":"212","author":"Bollengier","year":"1976","journal-title":"J Neurol"},{"key":"R67-1-20210203","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1600-0404.1986.tb04587.x","article-title":"Multimodal evoked responses and cerebrospinal fluid oligoclonal immunoglobulins in patients with multiple sclerosis.","volume":"73","author":"Ganes","year":"1986","journal-title":"Acta Neurol Scand"},{"key":"R68-1-20210203","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/brain\/awh486","article-title":"Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.","volume":"128","author":"Cepok","year":"2005","journal-title":"Brain"},{"key":"R69-1-20210203","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1212\/WNL.58.5.824","article-title":"Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS.","volume":"58","author":"Villar","year":"2002","journal-title":"Neurology"},{"key":"R70-1-20210203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.","volume":"349","author":"Berger","year":"2003","journal-title":"N Engl J Med"},{"key":"R71-1-20210203","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1212\/01.WNL.0000147259.34163.33","article-title":"Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis.","volume":"63","author":"Gaertner","year":"2004","journal-title":"Neurology"},{"key":"R72-1-20210203","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00415-006-0299-4","article-title":"Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF.","volume":"254","author":"Kuhle","year":"2007","journal-title":"J Neurol"},{"key":"R73-1-20210203","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMp030098","article-title":"Do myelin-directed antibodies predict multiple sclerosis?","volume":"349","author":"Antel","year":"2003","journal-title":"N Engl J Med"},{"key":"R74-1-20210203","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jneuroim.2006.10.020","article-title":"Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection.","volume":"183","author":"Harp","year":"2007","journal-title":"J Neuroimmunol"},{"key":"R75-1-20210203","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.4049\/jimmunol.171.5.2725","article-title":"Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid.","volume":"171","author":"Owens","year":"2003","journal-title":"J Immunol"},{"key":"R76-1-20210203","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"R77-1-20210203","doi-asserted-by":"crossref","first-page":"11064","DOI":"10.1073\/pnas.0402455101","article-title":"Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis.","volume":"101","author":"Corcione","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R78-1-20210203","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jneuroim.2007.10.009","article-title":"Analysis of multiple sclerosis cerebrospinal fluid reveals a continuum of clonally related antibody-secreting cells that are predominantly plasma blasts.","volume":"192","author":"Winges","year":"2007","journal-title":"J Neuroimmunol"},{"key":"R79-1-20210203","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0008-8749(83)90250-2","article-title":"Isolation of myelin basic protein-reactive T-cell lines from normal human blood.","volume":"81","author":"Burns","year":"1983","journal-title":"Cell Immunol"},{"key":"R80-1-20210203","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3.","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"R81-1-20210203","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1126\/science.1142331","article-title":"Emerging challenges in regulatory T cell function and biology.","volume":"317","author":"Sakaguchi","year":"2007","journal-title":"Science"},{"key":"R82-1-20210203","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20031579","article-title":"Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.","volume":"199","author":"Viglietta","year":"2004","journal-title":"J Exp Med"},{"key":"R83-1-20210203","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1002\/eji.200526065","article-title":"Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis.","volume":"35","author":"Haas","year":"2005","journal-title":"Eur J Immunol"},{"key":"R84-1-20210203","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jneuroim.2006.08.003","article-title":"CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis.","volume":"180","author":"Kumar","year":"2006","journal-title":"J Neuroimmunol"},{"key":"R85-1-20210203","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/jnr.20852","article-title":"Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.","volume":"83","author":"Venken","year":"2006","journal-title":"J Neurosci Res"},{"key":"R86-1-20210203","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jnr.20522","article-title":"Decreased FOXP3 levels in multiple sclerosis patients.","volume":"81","author":"Huan","year":"2005","journal-title":"J Neurosci Res"},{"key":"R87-1-20210203","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1365-2249.2006.03271.x","article-title":"Increased frequency of CD4+CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients.","volume":"147","author":"Feger","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"R89-1-20210203","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1172\/JCI21357","article-title":"Multiple sclerosis.","volume":"113","author":"Hafler","year":"2004","journal-title":"J Clin Invest"},{"key":"R90-1-20210203","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0165-5728(00)00230-7","article-title":"The role of costimulation in autoimmune demyelination.","volume":"107","author":"Racke","year":"2000","journal-title":"J Neuroimmunol"},{"key":"R91-1-20210203","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1096\/fj.03-0199fje","article-title":"Constitutive expression of a costimulatory ligand on antigen-presenting cells in the nervous system drives demyelinating disease.","volume":"17","author":"Zehntner","year":"2003","journal-title":"FASEB J"},{"key":"R92-1-20210203","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1172\/JCI1528","article-title":"Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated\/memory T cells.","volume":"101","author":"Lovett-Racke","year":"1998","journal-title":"J Clin Invest"},{"key":"R93-1-20210203","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.4049\/jimmunol.178.6.3447","article-title":"B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis.","volume":"178","author":"Mann","year":"2007","journal-title":"J Immunol"},{"key":"R94-1-20210203","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"R95-1-20210203","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.4049\/jimmunol.170.7.3637","article-title":"B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy.","volume":"170","author":"Selenko-Gebauer","year":"2003","journal-title":"J Immunol"},{"key":"R96-1-20210203","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood-2006-12-062422","article-title":"Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.","volume":"110","author":"Goldberg","year":"2007","journal-title":"Blood"},{"key":"R97-1-20210203","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2004.06.013","article-title":"Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.","volume":"155","author":"Schreiner","year":"2004","journal-title":"J Neuroimmunol"},{"key":"R98-1-20210203","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1602\/neurorx.2.2.277","article-title":"Imaging of multiple sclerosis: role in neurotherapeutics.","volume":"2","author":"Bakshi","year":"2005","journal-title":"NeuroRx"},{"key":"R99-1-20210203","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/01.jnen.0000235119.52311.16","article-title":"Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis.","volume":"65","author":"Hochmeister","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"R100-1-20210203","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1191\/135248506ms1274oa","article-title":"Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.","volume":"12","author":"Fainardi","year":"2006","journal-title":"Mult Scler"},{"key":"R101-1-20210203","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1527-3458.2007.00010.x","article-title":"Glatiramer acetate in multiple sclerosis: a review.","volume":"13","author":"Ruggieri","year":"2007","journal-title":"CNS Drug Rev"},{"key":"R102-1-20210203","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1007\/BF00873697","article-title":"The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease.","volume":"243","author":"Ben-Nun","year":"1996","journal-title":"J Neurol"},{"key":"R103-1-20210203","first-page":"209","article-title":"Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses.","volume":"64","author":"Teitelbaum","year":"1996","journal-title":"J Neurol"},{"key":"R104-1-20210203","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1212\/WNL.56.6.702","article-title":"Mechanisms of action of glatiramer acetate in multiple sclerosis.","volume":"56","author":"Neuhaus","year":"2001","journal-title":"Neurology"},{"key":"R105-1-20210203","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0022-510X(83)90205-8","article-title":"Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE).","volume":"62","author":"Lisak","year":"1983","journal-title":"J Neurol Sci"},{"key":"R106-1-20210203","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1212\/WNL.36.1.92","article-title":"Human cellular immune response to copolymer I and myelin basic protein.","volume":"36","author":"Burns","year":"1986","journal-title":"Neurology"},{"key":"R107-1-20210203","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1172\/JCI8970","article-title":"Glatiramer acetate (Copaxone) induces degenerate, TH2-polarized immune responses in patients with multiple sclerosis.","volume":"105","author":"Duda","year":"2000","journal-title":"J Clin Invest"},{"key":"R108-1-20210203","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0165-5728(03)00170-X","article-title":"Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a TH2-biased phenotype.","volume":"140","author":"Dhib-Jalbut","year":"2003","journal-title":"J Neuroimmunol"},{"key":"R109-1-20210203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/135245850100700108","article-title":"Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells.","volume":"7","author":"Ragheb","year":"2001","journal-title":"Mult Scler"},{"key":"R110-1-20210203","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nm1620","article-title":"Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.","volume":"13","author":"Weber","year":"2007","journal-title":"Nat Med"},{"key":"R111-1-20210203","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1191\/1352458503ms932oa","article-title":"Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.","volume":"9","author":"Martinelli Boneschi","year":"2003","journal-title":"Mult Scler"},{"key":"R113-1-20210203","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ana.21079","article-title":"Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.","volume":"61","author":"Wolinsky","year":"2007","journal-title":"Ann Neurol"},{"issue":"suppl 3","key":"R114-1-20210203","first-page":"iii28","article-title":"Long-term experience with interferon beta-1b (Betaferon) in multiple sclerosis.","volume":"252","author":"Arnason","year":"2005","journal-title":"J Neurol"},{"issue":"suppl 3","key":"R115-1-20210203","first-page":"iii44","article-title":"Early treatment and dose optimisation BENEFIT and BEYOND.","volume":"252","author":"Hartung","year":"2005","journal-title":"J Neurol"},{"key":"R116-1-20210203","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine.","volume":"6","author":"Borden","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"suppl 5","key":"R117-1-20210203","doi-asserted-by":"crossref","first-page":"v12","DOI":"10.1007\/s00415-004-1504-y","article-title":"What do we know about the mechanism of action of disease-modifying treatments in MS?","volume":"251","author":"Hartung","year":"2004","journal-title":"J Neurol"},{"key":"R118-1-20210203","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ana.21119","article-title":"Interferon-beta for multiple sclerosis: long-term benefits?","volume":"61","author":"Rudick","year":"2007","journal-title":"Ann Neurol"},{"key":"R119-1-20210203","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.","volume":"43","year":"1993","journal-title":"Neurology"},{"key":"R120-1-20210203","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"R121-1-20210203","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"R122-1-20210203","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.410430114","article-title":"Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.","volume":"43","author":"Simon","year":"1998","journal-title":"Ann Neurol"},{"issue":"suppl 5","key":"R123-1-20210203","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.1007\/s10072-006-0697-5","article-title":"Interferon after 10 years in patients with multiple sclerosis.","volume":"27","author":"Pozzilli","year":"2006","journal-title":"Neurol Sci"},{"key":"R124-1-20210203","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1212\/01.wnl.0000277703.74115.d2","article-title":"Interferon-beta: mechanism of action and dosing issues.","volume":"68","author":"Markowitz","year":"2007","journal-title":"Neurology"},{"key":"R125-1-20210203","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s004010100444","article-title":"Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis.","volume":"103","author":"Leussink","year":"2002","journal-title":"Acta Neuropathol (Berl)"},{"key":"R126-1-20210203","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1527-3458.2007.00003.x","article-title":"Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases.","volume":"13","author":"Stuve","year":"2007","journal-title":"CNS Drug Rev"},{"key":"R127-1-20210203","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"R128-1-20210203","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"R129-1-20210203","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.","volume":"354","author":"Yousry","year":"2006","journal-title":"N Engl J Med"},{"key":"R130-1-20210203","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis.","volume":"348","author":"Miller","year":"2003","journal-title":"N Engl J Med"},{"key":"R131-1-20210203","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/nn1005-1275","article-title":"Natalizumab and PML.","volume":"8","author":"Ransohoff","year":"2005","journal-title":"Nat Neurosci"},{"key":"R132-1-20210203","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1179\/016164106X98189","article-title":"Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.","volume":"28","author":"Bennett","year":"2006","journal-title":"Neurol Res"},{"key":"R133-1-20210203","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/01.nrl.0000263760.53418.5b","article-title":"Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.","volume":"13","author":"Johnson","year":"2007","journal-title":"Neurologist"},{"issue":"suppl 3","key":"R134-1-20210203","first-page":"iii34","article-title":"Aggressive multiple sclerosis-is there a role for stem cell transplantation?","volume":"252","author":"Havrdova","year":"2005","journal-title":"J Neurol"},{"key":"R135-1-20210203","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/brain\/awh117","article-title":"Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis.","volume":"127","author":"Sun","year":"2004","journal-title":"Brain"},{"key":"R136-1-20210203","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood.V62.4.873.873","article-title":"Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement.","volume":"62","author":"Hale","year":"1983","journal-title":"Blood"},{"key":"R137-1-20210203","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood-2002-04-1093","article-title":"Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.","volume":"101","author":"Ratzinger","year":"2003","journal-title":"Blood"},{"key":"R138-1-20210203","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev.med.58.071105.111552","article-title":"New therapeutic approaches for multiple sclerosis.","volume":"58","author":"De Jager","year":"2007","journal-title":"Annu Rev Med"},{"key":"R140-1-20210203","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/mol.65.1.227","article-title":"The antileukemia drug 2-chloro-2-deoxyadenosine: an intrinsic transcriptional antagonist.","volume":"65","author":"Hartman","year":"2004","journal-title":"Mol Pharmacol"},{"key":"R141-1-20210203","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1586\/14737175.5.6.721","article-title":"Cladribine for multiple sclerosis: review and current status.","volume":"5","author":"Sipe","year":"2005","journal-title":"Expert Rev Neurother"},{"key":"R142-1-20210203","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","article-title":"Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.","volume":"180","author":"Cross","year":"2006","journal-title":"J Neuroimmunol"},{"key":"R143-1-20210203","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archneur.62.2.258","article-title":"Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.","volume":"62","author":"Monson","year":"2005","journal-title":"Arch Neurol"},{"key":"R144-1-20210203","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"R145-1-20210203","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1073\/pnas.0402653101","article-title":"Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.","volume":"101","author":"Bielekova","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R146-1-20210203","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/ana.20287","article-title":"Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody.","volume":"56","author":"Rose","year":"2004","journal-title":"Ann Neurol"},{"key":"R147-1-20210203","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1073\/pnas.0601335103","article-title":"Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.","volume":"103","author":"Bielekova","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R148-1-20210203","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease.","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"R149-1-20210203","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator.","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"R150-1-20210203","doi-asserted-by":"crossref","first-page":"15978","DOI":"10.1074\/jbc.274.23.15978","article-title":"Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase.","volume":"274","author":"Mukhopadhyay","year":"1999","journal-title":"J Biol Chem"},{"key":"R151-1-20210203","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.","volume":"189","author":"Schneider","year":"1999","journal-title":"J Exp Med"},{"key":"R152-1-20210203","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/jlb.65.5.680","article-title":"TALL-1 is a novel member of the TNF family that is down-regulated by mitogens.","volume":"65","author":"Shu","year":"1999","journal-title":"J Leukoc Biol"},{"key":"R153-1-20210203","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1074-7613(01)00183-2","article-title":"TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS.","volume":"15","author":"Gross","year":"2001","journal-title":"Immunity"},{"key":"R154-1-20210203","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00228-007-0311-7","article-title":"Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.","volume":"63","author":"Munafo","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R155-1-20210203","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1002\/art.23047","article-title":"Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.","volume":"56","author":"Dall'era","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R156-1-20210203","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/art.23178","article-title":"Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.","volume":"58","author":"Tak","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R157-1-20210203","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1600-6143.2004.00476.x","article-title":"FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.","volume":"4","author":"Brinkmann","year":"2004","journal-title":"Am J Transplant"},{"key":"R158-1-20210203","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis.","volume":"355","author":"Kappos","year":"2006","journal-title":"N Engl J Med"},{"key":"R159-1-20210203","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1212\/01.WNL.0000154520.48391.69","article-title":"Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.","volume":"64","author":"Polman","year":"2005","journal-title":"Neurology"},{"key":"R160-1-20210203","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1212\/01.wnl.0000203121.04509.31","article-title":"A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.","volume":"66","author":"O'Connor","year":"2006","journal-title":"Neurology"},{"key":"R161-1-20210203","first-page":"955","article-title":"Drug evaluation: BG-12, an immunomodulatory dimethylfumarate.","volume":"8","author":"Wakkee","year":"2007","journal-title":"Curr Opin Investig Drugs"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/WNF.0b013e3181880359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:53:59Z","timestamp":1786038839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-200905000-00001"}},"subtitle":["Therapeutic Implications"],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":157,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3181880359","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}